LSD-Assisted Therapy for End-of-Life Anxiety: Annual Report Submitted to FDA

On May 2, 2012, the MAPS clinical team submitted to the FDA the annual report (PDF) for our ongoing long-term follow-up to our Swiss study of LSD-assisted psychotherapy for anxiety associated with life-threatening illness. The report summarizes the current status of the study, including information about enrollment and subject demographics, amendments to the study protocol, and the occurrence of any adverse events associated with participation in the study. Lead investigator Peter Gasser, M.D., several Swiss co-authors, and the MAPS clinical team are currently preparing a paper about the results to be submitted for publication in a peer-reviewed scientific journal.